Skip to main content

Advertisement

Figure 1 | BMC Cancer

Figure 1

From: Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Figure 1

Correlation analyses between MGMT, ABCB1 and ABCG2 mRNA expression and mean promoter methylation as well as comparison of MGMT, ABCB1 and ABCG2 promoter methylation between glioblastoma and non-malignant brain samples. Correlation analysis of mRNA expression [2-∆∆CT] and promoter methylation [%] was performed for 20 GBM specimens (A, C, E). Comparison of MGMT promoter methylation [%] between 64 GBM and 7 non-malignant brain specimens (B, D, F) (A) Correlation of MGMT mRNA expression and MGMT promoter methylation (Spearman’s rank correlation coefficient: -0.474; p = 0.035), (C) ABCB1 mRNA expression and ABCB1 promoter methylation (Spearman’s rank correlation coefficient: 0.242, p = 0.304), and (E) ABCG2 mRNA expression and ABCG2 promoter methylation (Spearman’s rank correlation coefficient: -0.170, p = 0.474). (B) Comparison of MGMT promoter methylation between GBM and non-malignant brain specimens (Mann–Whitney U test, p < 0.001), (D) ABCB1 promoter methylation between GBM and non-malignant brain samples (Mann–Whitney U test, p = 0.007), and (F) ABCG2 promoter methylation between GBM and non-malignant brain specimens (Mann–Whitney U test, p = 0.051).

Back to article page